Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 6/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12125243 | 1.00 | MAPK1 (0.39) | MAPK1GRM5HSD11B1MAPK8MAPK9 | |
| SCHEMBL1332249 | 1.00 | MAPK1 (0.39) | MAPK1GRM5HSD11B1MAPK8MAPK9 | |
| SCHEMBL1332253 | 1.00 | MAPK1 (0.39) | MAPK1GRM5HSD11B1MAPK8MAPK9 | |
| SCHEMBL1032650 | 1.00 | MAPK1 (0.39) | MAPK1GRM5HSD11B1MAPK8MAPK9 | |
| SCHEMBL1032648 | 1.00 | MAPK1 (0.39) | MAPK1GRM5HSD11B1MAPK8MAPK9 | |
| SCHEMBL1333951 | 0.95 | MAPK8 (0.39) | MAPK1GRM5HSD11B1MAPK8MAPK9 | |
| SCHEMBL1333954 | 0.95 | MAPK8 (0.39) | MAPK1GRM5HSD11B1MAPK8MAPK9 | |
| SCHEMBL1334443 | 0.92 | CNR2 (0.39) | MAPK1GRM5MAPK8MAPK9MAPK10 | |
| SCHEMBL1033719 | 0.92 | CNR2 (0.39) | MAPK1GRM5MAPK8MAPK9MAPK10 | |
| SCHEMBL1033715 | 0.92 | CNR2 (0.39) | MAPK1GRM5MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011008931-A2 | ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | WO | claimed |
| US-8513242-B2 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CYSTIC FIBROSIS FOUNDATION | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CFTR, GPR17, TYMS | MAPK1 4410/4885GRM5 2764/4885HSD11B1 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.